

RECEIVED
CENTRAL FAX CENTER

Law Offices of Albert Wai-Kit Chan, LLC

OCT 19 2006

World Plaza, Suite 604, 141-07 20th Avenue • Whitestone, NY 11357

Tel: (718) 799-1000 • Fax: (718) 357-8615 e-mail: chank@kitchanlaw.com

PLEASE DELIVER THE FOLLOWING PAGES

TO : UNITED STATES PATENT AND TRADEMARK OFFICE

COMPANY : UNITED STATES PATENT AND TRADEMARK OFFICE

FAX NO. : (571) 273-8300

FROM : ALBERT WAI-KIT CHAN/ah

U.S. SERIAL NO. : 10/593,217

RE : KING et al., for COMBINATION THERAPY COMPRISING CLORETAZINE™, U.S. Serial No. 10/593,217, filed September 15, 2006, National Stage Application of International Application No. PCT/US2005/010152, filed March 25, 2005, which claims priority of U.S. Serial No. 60/556,565, filed March 26, 2004 – Our Dkt #891-A-PCT-US

TOTAL NUMBER OF PAGES, INCLUDING COVER SHEET: 10DATE : October 19, 2006

* IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS POSSIBLE TO (718) 799-1000.

Message

Applicant : KING, et al. File No.: 891-A-PCT-US
Client : Vion Pharmaceuticals, Inc.
Date : October 19, 2006

Please see the attached Information Disclosure Statement for the above-identified application.

I hereby certify that the enclosed paper is being facsimile transmitted to: United States Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 at (571) 273-8300 on the date shown below.

Albert Wai-Kit Chan 10/19/06
Albert Wai-Kit Chan Date
Reg. No. 36,479

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED SOLELY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENT(S) NAMED ABOVE. THIS TRANSMISSION MAY CONTAIN INFORMATION THAT IS CONFIDENTIAL UNDER THE CLIENT AND ATTORNEY RELATIONSHIP. IF THE READER OF THIS MESSAGE IS NOT A DESIGNATED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO A DESIGNATED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, OR IF UPON READING THIS DOCUMENT YOU HAVE REASON TO BELIEVE THAT THE DOCUMENT WAS INADVERTENTLY SENT TO YOU, PLEASE NOTIFY US IMMEDIATELY BY COLLECT TELEPHONE CALL AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

Dkt #891-A-PCT-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**RECEIVED
CENTRAL FAX CENTER**

OCT 19 2006

Applicants : King, et al.

U.S. Serial No. : 10/593,217, National Stage Application of
International Application No.
PCT/US2005/010152, filed March 25, 2005,
claiming priority of U.S. Serial
No.60/556,565, filed March 26, 2004

Filed : September 15, 2006

For : COMBINATION THERAPY COMPRISING
CLORETAZINE™

Law Offices of Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

October 19, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, Applicants would like to direct the Examiner's attention to the following references which are listed below and on Form PTO/SB/08B (which is attached hereto as **Exhibit A**), and further attached as **Exhibits 1** (4 pages)

1. PCT International Preliminary Report on Patentability for VION Pharmaceuticals, et al., Int'l Application No. PCT/US2005/010152, Filed March 25, 2005, Dated September 26, 2006 [**Exhibit 1**]

Applicants : KING, et al.
U.S. Serial No. : 10/593,217
Filing Date : September 15, 2006
Page : 2

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of the Information Disclosure Statement. However, if additional fees are required, authorization is given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai Kit Chan

I hereby certify that this paper is being facsimile-transmitted to:	
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
<u>Albert Wai Kit Chan</u>	10/19/06
Albert Wai-Kit Chan	Date
Reg. No. 36,479	

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant(s)
Law Offices of
Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
E-mail: chank@kitchanlaw.com

Exhibit A

**RECEIVED
CENTRAL FAX CENTER**

OCT 19 2006

PTO/SE/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>		Complete if Known	
		Application Number	10/593,217
		Filing Date	September 15, 2006
		First Named Inventor	King, et al.
		Art Unit	Not Yet Known
		Examiner Name	Not Yet Known
Sheet 1	of 1	Attorney Docket Number	891-A-PCT-US

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Exhibit 1